One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription for Some or Most of Their HIV Patients in the

One in Four Surveyed EU5 Physicians Has Been Required to Change a Prescription
for Some or Most of Their HIV Patients in the Past Twelve Months, Primarily to
                                 Reduce Costs

EU5 Payers Agree that Amid Tightening Healthcare Budgets, the Growing Cost of
Brands and Increasing Availability of Generics Makes HIV an Attractive Target
for Cost Containment, According to a New Report from Decision Resources

PR Newswire

BURLINGTON, Mass., June 18, 2013

BURLINGTON, Mass., June 18, 2013 /PRNewswire/ -- Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, finds that, over the past 12 months, 25 percent of surveyed
physicians from the EU5 (France, Germany, Italy, Spain and the United Kingdom)
have been required to change the antiretroviral (ARV) prescription for some or
most of their HIV patients, primarily to reduce costs. Additionally, more than
40 percent of respondents report that changing prescriptions is strongly
encouraged or that they give preference to lower priced ARVs. These findings
reflect the tightening healthcare budgets throughout the EU5 as over 20
percent of surveyed physicians indicate that their budgets for ARV treatments
have decreased in the last year.

(Logo: )

The new European Physician and Payer Forum report entitled The Approaching
Cliff: How Will the Availability of Generic Antiretrovirals Impact the EU5
Prescribing and Reimbursement Landscape for Current and Emerging Brands in
HIV? finds that surveyed physicians currently prescribe once-daily, single
tablet regimens (STRs), such as Gilead/Bristol-Myers Squibb's Atripla and
Gilead/Janssen's Eviplera to more than 40 percent of their HIV patients.
Furthermore, despite cost containment efforts from payers and the upcoming
generic availability of some STR components, the convenience of one pill dosed
once daily, the recent launch of Gilead's integrase inhibitor-based STR
Stribild, and the anticipated availability of ViiV's 572-Trii will drive
respondents to expand use of STRs to half of their HIV patients by the end of

The report also finds that the serious public health threat posed by ongoing
transmission of HIV and pushback from well-organized and influential patient
advocates will constrain payers' ability to mandate use of cheaper multi-pill
regimens. However, interviewed payers do believe that declining budgets and
increasing numbers of patients requiring treatment will drive physicians to
"break" coformulated, single pill products into multi-pill regimens to some
extent in order to capture generic savings and meet their growing clinical

"Historically, new HIV agents have not been subjected to cost-effectiveness
analyses owing to the serious public health threat posed by HIV infections and
limited availability of effective drugs," said Decision Resources Analyst
Seamus Levine-Wilkinson, Ph.D. "However, the pressure to reduce costs while
providing treatment to more patients will drive increasingly stringent payer
reviews in which competitive pricing and regionally tailored dossiers will
play critical roles in securing formulary placement. Payers in the United
Kingdom, in particular, warn that companies that resist price negotiations are
being unrealistic and run the risk of losing out to more amenable drug

About Decision Resources
Decision Resources ( is a world leader in market
research publications, advisory services and consulting designed to help
clients shape strategy, allocate resources and master their chosen markets.
Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group at

All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.

SOURCE Decision Resources

Contact: Decision Resources Group, Christopher Comfort, 781-993-2597,
Press spacebar to pause and continue. Press esc to stop.